I1 receptors, cardiovascular function, and metabolism

American Journal of Hypertension

Volumn 14, Issue 11 II, 2001, Pages

  Bousquet, Pascal ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Clonidine; Hypertension; Imidazoline receptors; Rilmenidine; 2 adrenergic receptors

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ANILINE DERIVATIVE; CATECHOLAMINE; CLONIDINE; IMIDAZOLINE DERIVATIVE; IMIDAZOLINE I1 RECEPTOR; RILMENIDINE; ADRENERGIC ALPHA AGONISTS; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; DRUG RECEPTOR; IMIDAZOLINE RECEPTOR 1; OXAZOLE DERIVATIVE;

ANTIHYPERTENSIVE ACTIVITY; BINDING AFFINITY; BINDING SITE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR FUNCTION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG RECEPTOR BINDING; HUMAN; HYPERTENSION; INSULIN RELEASE; KIDNEY TUBULE ABSORPTION; LONG TERM EXPOSURE; PRIORITY JOURNAL; REGULATORY MECHANISM; SIDE EFFECT; CARDIOVASCULAR SYSTEM; DRUG EFFECT; KIDNEY; METABOLISM; PANCREAS; REVIEW; TREATMENT OUTCOME;

ADRENERGIC ALPHA-AGONISTS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR SYSTEM; CLONIDINE; HUMAN; HYPERTENSION; KIDNEY; OXAZOLES; PANCREAS; RECEPTORS, DRUG; TREATMENT OUTCOME;

EID: 0035514525     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(01)02238-5     Document Type: Conference Paper

References (78)

1. Comparison of the effects of clonidine on pre- and postsynaptic adrenoceptors in the rabbit pulmonary artery, α-sympathomimetic inhibition of neurogenic vasoconstriction
2. Clonidine
3. 2-adrenergic effects of phenylethylamines and imidazolines
4. Central alpha-adrenergic systems as targets for hypotensive drugs
5. 2-Adrenoceptors: Classification, localization, mechanisms and target for drugs
6. Evidence for direct alpha-adrenoceptor stimulation of effector neurons in cardiovascular centers by clonidine
7. Action of α-adrenergic blocking drugs on the sympathetic centres and their interactions with the central sympatho-inhibitory effect of clonidine
8. Sedative effects of α-sympathomimetic drugs and their antagonism by adrenergic and cholinergic blocking drugs
9. 2-adrenoceptors affect sleep and arousal mechanisms
10. Localization of the central cardiovascular action of clonidine
11. The nucleus reticularis lateralis a region highly sensitive to clonidine
12. Lateral reticular formation as a site for morphine and clonidine induced hypotension
13. Central cardiovascular effects of α-adrenergic drugs: Difference between catecholamines and imidazolines
14. Clonidine-induced inhibition of sympathetic nerve activity: No indication for a central presynaptic or an indirect sympathomimetic mode of action
15. The central modulatory effect of clonidine on the cardiodepressor reflex after suppression of synthesis and storage of noradrenaline
16. The medullary cardiovascular effects of imidazolines and some GABA analogues: A review
17. Influence of central pretreatment with 6-hydroxydopamine on the hypotensive effect of clonidine
18. Role of imidazoline receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla
19. 2-adrenoceptors in the cardiovascular effects of moxonidine
20. 1-imidazoline binding site is a functional receptor mediating vasodepression via the ventral medulla
21. Evidence for the involvement of imidazoline receptors in the central hypotensive effect of rilmenidine in the rabbit
22. 2A-adrenergic receptor subtype
23. On the nature of the central hypotensive effect of clonidine and α-methyldopa
24. Relative importance of medullary brain nuclei for the sympatho-inhibitory actions of rilmenidine in the anaesthetized rabbit
25. 2-adrenoceptor subtypes in mediating central effects of catecholamines and imidazolines
26. 2-adrenergic receptors are not required for central anti-hypertensive action of moxonidine in mice
27. Central imidazoline receptors and centrally acting anti-hypertensive agents
28. 125I]para-iodoclonidine reveals a new subtype of imidazoline specific sites in synaptosomal plasma membranes of the bovine brainstem
29. An endogenous clonidine-displacing substance from bovine brain: Receptor binding and hypotensive actions in the ventrolateral medulla
30. Evidence for the existence of a homogenous population of imidazoline receptors in the human brainstem
31. Evidence for imidazoline binding sites in basolateral membranes from rabbit kidney
32. 3H]clonidine
33. 2-adrenoceptors in rabbit adipocyte membranes
34. High affinity binding of idazoxan to a non-catecholaminergic binding site in the central nervous system: Description of a putative idazoxan-receptor
35. 2-adrenoceptors in the ventro lateral medulla
36. 3H]idazoxan bind to different sites on rabbit forebrain and kidney membranes
37. 2-adrenergic receptor
38. Are there multiple imidazoline binding sites?
39. Purification and characterization of mitochondrial imidazoline-guanidinium receptive site from rabbit kidney
40. Localization of the imidazoline binding domain on monoamine oxidase B
41. 2-imidazoline sites
42. 2 sites
43. Presynaptic imidazoline receptors: New developments in characterization and classification
44. Isolation and characterization of imidazoline receptor protein from bovine adrenal chromaffin cells
45. 2-adrenoceptor and non adrenergic idazoxan-binding sites
46. Development of anti-idiotypic antibodies specific for the human cerebral imidazoline receptor
47. Isolation of a human cerebral imidazoline-specific binding protein
48. 2-adrenoceptors
49. Imidazoline receptor antisera selected (IRAS) cDNA: Cloning and characterization
50. 1-imidazoline receptors to diacylglyceride accumulation in PC12 rat pheochromocytoma cells
51. 1 imidazoline receptors to the cAMP pathway with a highly selective ligand, benazoline
52. Isolation of an endogenous clonidine-displacing substance form rat brain
53. Isolation and partial purification of a clonidine displacing endogenous brain substance
54. An endogenous substance with clonidine-like properties: Selective binding to imidazole sites in the ventrolateral medulla
55. An endogenous, non-catecholamine clonidine antagonist increases mean arterial blood pressure
56. Agmatine: An endogenous clonidine displacing substance in the brain
57. 1-imidazoline receptors
58. Rilmenidine
59. Moxonidine, a review of its pharmacology, and therapeutic use in essential hypertension
60. 1-imidazoline agonist moxonidine administered into the rostral ventrolateral medulla
61. Rilmenidine selectivity for imidazoline receptors in human brain
62. 1-imidazoline receptor: From binding site to therapeutic target in cardiovascular disease
63. Antiarrhythmic action of rilmenidine on adrenaline-induced arrhythmia via central imidazoline receptors in halothane-anesthetized dogs
64. Inhibition of centrally induced ventricular arrhythmias by rilmenidine and idazoxan in rabbits
65. Effect of moxonidine on arrhythmias induced by coronary artery occlusion and reperfusion
66. Pharmacological characterization of the imidazoline receptor which mediates inhibition of noradrenaline release in the rabbit pulmonary artery
67. Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine
68. Regression of left ventricular hypertrophy in hypertensive patients after a one-year treatment with rilmenidine: A double blind, randomised, controlled versus nifedipine study
69. Linksventrikuläre hypertrophieregression unter einer therapie mit moxonidin
70. Rilmenidine in patients with left ventricular hypertrophy due to essential hypertension: Beyond the reduction of left ventricular mass
71. Suppressing sympathetic activation in congestive heart failure
72. Renal effects of rilmenidine in anaesthetized rats: Importance of renal nerves
73. + channels in mouse pancreatic β-cells
74. ATP channels in insulin-secreting cells
75. 2 sites
76. Characterization of new efaroxan derivatives for use in purification of imidazoline-binding sites
77. Rilmenidine normalizes fructose-induced insulin resistance and hypertension in rats
78. Sympathetic nervous system in salt-sensitive and obese hypertension: Amelioration of multiple abnormalities by a central sympatholytic agent